<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767596</url>
  </required_header>
  <id_info>
    <org_study_id>LIX001</org_study_id>
    <nct_id>NCT02767596</nct_id>
  </id_info>
  <brief_title>Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog</brief_title>
  <official_title>A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laniado Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laniado Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to
      achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting
      GLP-1 analog.

      Patients who fail to achieve significant improvement in diabetes control on basal insulin and
      Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The
      primary outcomes will be changes in HBA1C and weight.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment rate
  </why_stopped>
  <start_date type="Actual">July 12, 2016</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin A1c</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal insulins</intervention_name>
    <description>patients are on basal insulin treatment</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>Glargine, Detemir, Degludec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with
        secondary failure of non-fasting glycemic control

        Exclusion Criteria:

          -  Pregnant or lactating woman

          -  Renal failure (eGFR&lt;30)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bildirici Diabetes Center, Laniado Hospital</name>
      <address>
        <city>Netanya</city>
        <zip>42150</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>treatment</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

